MSBase partners with Icometrix, Roche, Novartis and Biogen in world-first project


MSBase and icometrix collaborate to integrate MRI biomarkers in the MSBase Registry. Combining imaging data of thousands of people with MS with their clinical information will lead to insights into predictive tools for disease progression. This is an important step towards a more standardized use of MRI measures in a clinical setting.

The MSBase Registry is a unique international database dedicated to sharing, tracking and evaluating outcome data in Multiple Sclerosis (MS), including over 49000 patients. Until now, only descriptive MRI data was included in the MSBase Registry.

This ambitious, large-scale project, aims to include advanced analytics of routinely acquired MRI scans using the icometrix platform, MSmetrix. It will establish if disease progression of individuals with MS can be predicted early using MRI assessment, and potentially prevented. This investigator-initiated partnership between icometrix and the MSBase Foundation is currently supported by grants from three pharmaceutical companies, Novartis, Biogen and Roche.

Helmut Butzkueven, MSBase Director, adds: “We wish to unlock the power of MRI for personalized monitoring in MS. The MSBase Scientific Leadership Group has selected MRI integration as the top strategic priority for MSBase. We believe that already conducted MRI scans represent an enormous missed opportunity, because advanced measurements to assess change over time from these scans are not currently in practical use. We will test the predictive power of this unlocking of MRI data in the first phase, with a total of 10 000 MRI data points in at least 3 000 MS patients from all over the world.

Wim Van Hecke, CEO of icometrix, is excited to start the collaboration: “After the approval for clinical use of our MRI measures in the EU/Canada/Australia (CE) and the US (FDA), this is a next big milestone in our mission to provide accurate MRI monitoring to help radiologists, neurologists and people with MS worldwide.”